Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

Sirpa Leppä; Judit Jorgensen; Anne Tierens; Leo Meriranta; Ingunn Østlie; Peter de Nully Brown; Unn-Merete Fagerli; Thomas Stauffer Larsen; Susanna Mannisto; Lars Munksgaard; Martin Maisenholder; Kaija Vasala; Peter Meyer; Mats Jerkeman; Magnus Bjorkholm; Oystein Fluge; Sirkku Jyrkklo; Knut Liestol; Elisabeth Ralfkiaer; Signe Spetalen; Klaus Beiske; Marja-Liisa Karjalainen-Lindsberg; Harald Holte

doi:10.1182/bloodadvances.2020001518

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

Sirpa Leppä, Judit Jorgensen, Anne Tierens, Leo Meriranta, Ingunn Østlie, Peter de Nully Brown, Unn-Merete Fagerli, Thomas Stauffer Larsen, Susanna Mannisto, Lars Munksgaard, Martin Maisenholder, Kaija Vasala, Peter Meyer, Mats Jerkeman, Magnus Bjorkholm, Oystein Fluge, Sirkku Jyrkklo, Knut Liestol, Elisabeth Ralfkiaer, Signe SpetalenKlaus Beiske, Marja-Liisa Karjalainen-Lindsberg, Harald Holte

Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu

Alkuperäiskieli	englanti
Lehti	Blood advances
Vuosikerta	4
Numero	9
Sivut	1906-1915
Sivumäärä	10
ISSN	2473-9529
DOI - pysyväislinkit	https://doi.org/10.1182/bloodadvances.2020001518
Tila	Julkaistu - 12 toukokuuta 2020
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Tieteenalat

3122 Syöpätaudit

Pääsy asiakirjaan

10.1182/bloodadvances.2020001518

advancesadv2020001518Lopullinen julkaistu versio, 1,07 MBLisenssi: Määrittelemätön

Siteeraa tätä

Leppä, S., Jorgensen, J., Tierens, A., Meriranta, L., Østlie, I., Brown, P. D. N., Fagerli, U-M., Larsen, T. S., Mannisto, S., Munksgaard, L., Maisenholder, M., Vasala, K., Meyer, P., Jerkeman, M., Bjorkholm, M., Fluge, O., Jyrkklo, S., Liestol, K., Ralfkiaer, E., ... Holte, H. (2020). Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. Blood advances, 4(9), 1906-1915. https://doi.org/10.1182/bloodadvances.2020001518

Leppä, Sirpa ; Jorgensen, Judit ; Tierens, Anne ; Meriranta, Leo ; Østlie, Ingunn ; Brown, Peter de Nully ; Fagerli, Unn-Merete ; Larsen, Thomas Stauffer ; Mannisto, Susanna ; Munksgaard, Lars ; Maisenholder, Martin ; Vasala, Kaija ; Meyer, Peter ; Jerkeman, Mats ; Bjorkholm, Magnus ; Fluge, Oystein ; Jyrkklo, Sirkku ; Liestol, Knut ; Ralfkiaer, Elisabeth ; Spetalen, Signe ; Beiske, Klaus ; Karjalainen-Lindsberg, Marja-Liisa ; Holte, Harald. / Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. Julkaisussa: Blood advances. 2020 ; Vuosikerta 4, Nro 9. Sivut 1906-1915.

@article{37e78ecb17214acdafecda46ee35b029,

title = "Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis",

keywords = "B-CELL LYMPHOMA, NON-HODGKIN-LYMPHOMA, DOUBLE-HIT LYMPHOMA, LEPTOMENINGEAL DISEASE, AGGRESSIVE LYMPHOMA, ELDERLY-PATIENTS, YOUNG-PATIENTS, PHASE-II, RITUXIMAB, METHOTREXATE, 3122 Cancers",

author = "Sirpa Lepp{\"a} and Judit Jorgensen and Anne Tierens and Leo Meriranta and Ingunn {\O}stlie and Brown, {Peter de Nully} and Unn-Merete Fagerli and Larsen, {Thomas Stauffer} and Susanna Mannisto and Lars Munksgaard and Martin Maisenholder and Kaija Vasala and Peter Meyer and Mats Jerkeman and Magnus Bjorkholm and Oystein Fluge and Sirkku Jyrkklo and Knut Liestol and Elisabeth Ralfkiaer and Signe Spetalen and Klaus Beiske and Marja-Liisa Karjalainen-Lindsberg and Harald Holte",

year = "2020",

month = may,

day = "12",

doi = "10.1182/bloodadvances.2020001518",

language = "English",

volume = "4",

pages = "1906--1915",

journal = "Blood advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "9",

}

Leppä, S, Jorgensen, J, Tierens, A, Meriranta, L, Østlie, I, Brown, PDN, Fagerli, U-M, Larsen, TS, Mannisto, S, Munksgaard, L, Maisenholder, M, Vasala, K, Meyer, P, Jerkeman, M, Bjorkholm, M, Fluge, O, Jyrkklo, S, Liestol, K, Ralfkiaer, E, Spetalen, S, Beiske, K, Karjalainen-Lindsberg, M-L & Holte, H 2020, 'Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis', Blood advances, Vuosikerta 4, Nro 9, Sivut 1906-1915. https://doi.org/10.1182/bloodadvances.2020001518

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. / Leppä, Sirpa; Jorgensen, Judit; Tierens, Anne; Meriranta, Leo; Østlie, Ingunn; Brown, Peter de Nully; Fagerli, Unn-Merete; Larsen, Thomas Stauffer; Mannisto, Susanna; Munksgaard, Lars; Maisenholder, Martin; Vasala, Kaija; Meyer, Peter; Jerkeman, Mats; Bjorkholm, Magnus; Fluge, Oystein; Jyrkklo, Sirkku; Liestol, Knut; Ralfkiaer, Elisabeth; Spetalen, Signe; Beiske, Klaus; Karjalainen-Lindsberg, Marja-Liisa; Holte, Harald.

julkaisussa: Blood advances, Vuosikerta 4, Nro 9, 12.05.2020, s. 1906-1915.

Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu

TY - JOUR

T1 - Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

AU - Leppä, Sirpa

AU - Jorgensen, Judit

AU - Tierens, Anne

AU - Meriranta, Leo

AU - Østlie, Ingunn

AU - Brown, Peter de Nully

AU - Fagerli, Unn-Merete

AU - Larsen, Thomas Stauffer

AU - Mannisto, Susanna

AU - Munksgaard, Lars

AU - Maisenholder, Martin

AU - Vasala, Kaija

AU - Meyer, Peter

AU - Jerkeman, Mats

AU - Bjorkholm, Magnus

AU - Fluge, Oystein

AU - Jyrkklo, Sirkku

AU - Liestol, Knut

AU - Ralfkiaer, Elisabeth

AU - Spetalen, Signe

AU - Beiske, Klaus

AU - Karjalainen-Lindsberg, Marja-Liisa

AU - Holte, Harald

PY - 2020/5/12

Y1 - 2020/5/12

KW - B-CELL LYMPHOMA

KW - NON-HODGKIN-LYMPHOMA

KW - DOUBLE-HIT LYMPHOMA

KW - LEPTOMENINGEAL DISEASE

KW - AGGRESSIVE LYMPHOMA

KW - ELDERLY-PATIENTS

KW - YOUNG-PATIENTS

KW - PHASE-II

KW - RITUXIMAB

KW - METHOTREXATE

KW - 3122 Cancers

U2 - 10.1182/bloodadvances.2020001518

DO - 10.1182/bloodadvances.2020001518

M3 - Article

VL - 4

SP - 1906

EP - 1915

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 9

ER -